Novel Agents Targeting the IGF-1R/PI3K Pathway Impair Cell Proliferation and Survival in Subsets of Medulloblastoma and Neuroblastoma

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wojtalla, Anna ^a   Salm, Fabiana ^a   Christiansen, Ditte G ^a   Cremona, Tiziana ^b   Cwiek, Paulina ^a   Shalaby, Tarek ^b   Gross, Nicole ^c   Grotzer, Michael A ^b   Arcaro, Alexandre ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY R 1507; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PIK 75; R 1507; SMALL INTERFERING RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IGF 1R PI3K SIGNALING PATHWAY; MEDULLOBLASTOMA; NEUROBLASTOMA; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MEDULLOBLASTOMA; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84867300753     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047109     Document Type: Article

References (78)

1. Schwab M, Praml C, Amler LC, (1996) Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 16: 211-229.
2. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248.
3. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, et al. (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91: 680-686.
4. Van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, et al. (2001) Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes Cancer 32: 126-135.
5. Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, et al. (1997) Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Cancer Genet Cytogenet 97: 135-142.
6. Van Roy N, Cheng NC, Laureys G, Opdenakker G, Versteeg R, et al. (1995) Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. Eur J Cancer 31A: 530-535.
7. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
8. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, et al. (1996) EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7: 429-437.
9. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, et al. (1996) Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14: 1245-1251.
10. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A, (2009) Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 9: 176-188.
11. Cianfarani S, Rossi P, (1997) Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. Eur J Pediatr 156: 256-261.
12. Wechsler-Reya R, Scott MP, (2001) The developmental biology of brain tumors. Annu Rev Neurosci 24: 385-428.
13. Gilbertson R, (2002) Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 38: 675-685.
14. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462-6466.
15. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT, (2009) The insulin-like growth factor system and sarcomas. J Pathol 217: 469-482.
16. Kim SY, Wan X, Helman LJ, (2009) Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull Cancer 96: E52-60.
17. Kim SY, Toretsky JA, Scher D, Helman LJ, (2009) The role of IGF-1R in pediatric malignancies. Oncologist 14: 83-91.
18. Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, et al. (2006) Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 12: 6772-6780.
19. Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, et al. (2007) Preclinical in vivo study of new insulin-like growth factor-I receptor - specific inhibitor in Ewing's sarcoma. Clin Cancer Res 13: 1322-1330.
20. Guerreiro AS, Boller D, Shalaby T, Grotzer MA, Arcaro A, (2006) Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer 119: 2527-2538.
21. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, et al. (2006) Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 12: 3532-3540.
22. Pollak M, (2008) Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8: 384-392.
23. Pollak M, (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
24. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, et al. (2010) A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465.
25. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, et al. (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29: 4541-4547.
26. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, et al. (1990) Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 86: 1806-1814.
27. Kuwahara Y, Hosoi H, Osone S, Kita M, Iehara T, et al. (2004) Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res 10: 5940-5948.
28. Wewetzer K, Janet T, Heymann D, Unsicker K, (1993) Cell blotting and isoelectric focusing of neuroblastoma-derived heparin-binding neurotrophic activities: detection of basic fibroblast growth factor protein and mRNA. J Neurosci Res 36: 209-215.
29. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC, (1994) Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 84: 3465-3472.
30. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J, (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272-3280.
31. Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, et al. (1998) Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 58: 3932-3941.
32. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, et al. (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29: 143-152.
33. Andrae J, Molander C, Smits A, Funa K, Nister M, (2002) Platelet-derived growth factor-B and-C and active alpha-receptors in medulloblastoma cells. Biochem Biophys Res Commun 296: 604-611.
34. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, et al. (2001) Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 20: 3857-3868.
35. Nakagawara A, (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169: 107-114.
36. Duplan SM, Theoret Y, Kenigsberg RL, (2002) Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 8: 246-257.
37. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ, (2004) Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55.
38. D'Cunja J, Shalaby T, Rivera P, von Buren A, Patti R, et al. (2007) Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer 43: 1581-1589.
39. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, et al. (2007) Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 406: 57-66.
40. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
41. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935.
42. Marinov M, Fischer B, Arcaro A, (2007) Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63: 172-182.
43. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, et al. (2010) R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55: 67-75.
44. Wojtalla A, Arcaro A (2011) Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol.
45. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, et al. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
46. Vanhaesebroeck B, Vogt PK, Rommel C, (2010) PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 347: 1-19.
47. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B, (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329-341.
48. Blajecka K, Borgstrom A, Arcaro A, (2011) Phosphatidylinositol 3-kinase isoforms as novel drug targets. Curr Drug Targets 12: 1056-1081.
49. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
50. Sansal I, Sellers WR, (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
51. Arcaro A, Guerreiro AS, (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8: 271-306.
52. Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, et al. (2009) Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 273: 336-346.
53. Hartmann W, Digon-Sontgerath B, Koch A, Waha A, Endl E, et al. (2006) Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019-3027.
54. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
55. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050.
56. Kenney AM, Widlund HR, Rowitch DH, (2004) Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 131: 217-228.
57. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. (2006) Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
58. Del Valle L, Enam S, Lassak A, Wang JY, Croul S, et al. (2002) Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 8: 1822-1830.
59. Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, et al. (2003) ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63: 140-148.
60. Kim B, van Golen CM, Feldman EL, (2004) Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene 23: 130-141.
61. Opel D, Poremba C, Simon T, Debatin KM, Fulda S, (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745.
62. Sartelet H, Oligny LL, Vassal G, (2008) AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 8: 757-769.
63. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412.
64. Garcia-Echeverria C, Sellers WR, (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526.
65. Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C, (2009) PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21: 194-198.
66. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
67. Courtney KD, Corcoran RB, Engelman JA, (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
68. Wong KK, Engelman JA, Cantley LC, (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90.
69. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, et al. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404: 449-458.
70. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, et al. (2008) Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14: 1172-1181.
71. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, et al. (1988) Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 130: 472-484.
72. He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, et al. (1991) Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest 64: 833-843.
73. Fults D, Pedone CA, Morse HG, Rose JW, McKay RD, (1992) Establishment and characterization of a human primitive neuroectodermal tumor cell line from the cerebral hemisphere. J Neuropathol Exp Neurol 51: 272-280.
74. von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart CG, et al. (2007) Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 7: 19.
75. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, et al. (2008) Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 14: 6761-6769.
76. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, et al. (2010) A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics 3: 26.
77. Bender A, Opel D, Naumann I, Kappler R, Friedman L, et al. (2011) PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 30: 494-503.
78. NCT00811993 CgI (First Received on December 18, 2008. Last Updated on March 15, 2011) A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors.